CHMP Meeting to Discuss Review of Multaq

CHMP will have a meeting Friday to discuss the ongoing review of the benefits and risks of Multaq (dronedarone).

The European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) is to have a meeting this Friday to discuss the ongoing review of the benefits and risks of Multaq (dronedarone).

Multaq has been authorised in the European Union since November 2009 for use in patients with atrial fibrillation, a condition where the upper chambers of the heart contract rapidly and in an irregular fashion.

The current review of Multaq began in January 2011 on the request of the European Commission, following reports of liver damage in two patients taking the medicine. In July 2011, the scope of the review was extended to also look at new data related to the effects of the medicine on the heart, blood vessels and lungs.

&n